126 related articles for article (PubMed ID: 11026535)
1. The structure of an HIV-1 specific cell entry inhibitor in complex with the HIV-1 gp41 trimeric core.
Zhou G; Ferrer M; Chopra R; Kapoor TM; Strassmaier T; Weissenhorn W; Skehel JJ; Oprian D; Schreiber SL; Harrison SC; Wiley DC
Bioorg Med Chem; 2000 Sep; 8(9):2219-27. PubMed ID: 11026535
[TBL] [Abstract][Full Text] [Related]
2. Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements.
Ferrer M; Kapoor TM; Strassmaier T; Weissenhorn W; Skehel JJ; Oprian D; Schreiber SL; Wiley DC; Harrison SC
Nat Struct Biol; 1999 Oct; 6(10):953-60. PubMed ID: 10504731
[TBL] [Abstract][Full Text] [Related]
3. Helical interactions in the HIV-1 gp41 core reveal structural basis for the inhibitory activity of gp41 peptides.
Shu W; Liu J; Ji H; Radigen L; Jiang S; Lu M
Biochemistry; 2000 Feb; 39(7):1634-42. PubMed ID: 10677212
[TBL] [Abstract][Full Text] [Related]
4. Development of HIV entry inhibitors targeted to the coiled-coil regions of gp41.
Jiang S; Debnath AK
Biochem Biophys Res Commun; 2000 Mar; 269(3):641-6. PubMed ID: 10720469
[TBL] [Abstract][Full Text] [Related]
5. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target.
Chan DC; Chutkowski CT; Kim PS
Proc Natl Acad Sci U S A; 1998 Dec; 95(26):15613-7. PubMed ID: 9861018
[TBL] [Abstract][Full Text] [Related]
6. A novel fluorescence intensity screening assay identifies new low-molecular-weight inhibitors of the gp41 coiled-coil domain of human immunodeficiency virus type 1.
Cai L; Gochin M
Antimicrob Agents Chemother; 2007 Jul; 51(7):2388-95. PubMed ID: 17452484
[TBL] [Abstract][Full Text] [Related]
7. Blocking HIV entry.
Buzko OV; Shokat KM
Nat Struct Biol; 1999 Oct; 6(10):906-8. PubMed ID: 10504719
[TBL] [Abstract][Full Text] [Related]
8. Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket.
Eckert DM; Malashkevich VN; Hong LH; Carr PA; Kim PS
Cell; 1999 Oct; 99(1):103-15. PubMed ID: 10520998
[TBL] [Abstract][Full Text] [Related]
9. A covalent inhibitor targeting an intermediate conformation of the fusogenic subunit of the HIV-1 envelope complex.
Jacobs A; Quraishi O; Huang X; Bousquet-Gagnon N; Nault G; Francella N; Alvord WG; Pham N; Soucy C; Robitaille M; Bridon D; Blumenthal R
J Biol Chem; 2007 Nov; 282(44):32406-13. PubMed ID: 17726011
[TBL] [Abstract][Full Text] [Related]
10. Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection.
Bianchi E; Finotto M; Ingallinella P; Hrin R; Carella AV; Hou XS; Schleif WA; Miller MD; Geleziunas R; Pessi A
Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12903-8. PubMed ID: 16129831
[TBL] [Abstract][Full Text] [Related]
11. A fluorescence assay for rapid detection of ligand binding affinity to HIV-1 gp41.
Gochin M; Savage R; Hinckley S; Cai L
Biol Chem; 2006 Apr; 387(4):477-83. PubMed ID: 16606347
[TBL] [Abstract][Full Text] [Related]
12. Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1.
Debnath AK; Radigan L; Jiang S
J Med Chem; 1999 Aug; 42(17):3203-9. PubMed ID: 10464007
[TBL] [Abstract][Full Text] [Related]
13. Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region.
Eckert DM; Kim PS
Proc Natl Acad Sci U S A; 2001 Sep; 98(20):11187-92. PubMed ID: 11572974
[TBL] [Abstract][Full Text] [Related]
14. Non-peptide entry inhibitors of HIV-1 that target the gp41 coiled coil pocket.
Stewart KD; Huth JR; Ng TI; McDaniel K; Hutchinson RN; Stoll VS; Mendoza RR; Matayoshi ED; Carrick R; Mo H; Severin J; Walter K; Richardson PL; Barrett LW; Meadows R; Anderson S; Kohlbrenner W; Maring C; Kempf DJ; Molla A; Olejniczak ET
Bioorg Med Chem Lett; 2010 Jan; 20(2):612-7. PubMed ID: 20004576
[TBL] [Abstract][Full Text] [Related]
15. A salt bridge between an N-terminal coiled coil of gp41 and an antiviral agent targeted to the gp41 core is important for anti-HIV-1 activity.
Jiang S; Debnath AK
Biochem Biophys Res Commun; 2000 Apr; 270(1):153-7. PubMed ID: 10733920
[TBL] [Abstract][Full Text] [Related]
16. A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody.
Jiang S; Lin K; Zhang L; Debnath AK
J Virol Methods; 1999 Jun; 80(1):85-96. PubMed ID: 10403680
[TBL] [Abstract][Full Text] [Related]
17. Viral surface glycoproteins, gp120 and gp41, as potential drug targets against HIV-1: brief overview one quarter of a century past the approval of zidovudine, the first anti-retroviral drug.
Teixeira C; Gomes JR; Gomes P; Maurel F; Barbault F
Eur J Med Chem; 2011 Apr; 46(4):979-92. PubMed ID: 21345545
[TBL] [Abstract][Full Text] [Related]
18. Design of a modular tetrameric scaffold for the synthesis of membrane-localized D-peptide inhibitors of HIV-1 entry.
Francis JN; Redman JS; Eckert DM; Kay MS
Bioconjug Chem; 2012 Jun; 23(6):1252-8. PubMed ID: 22545664
[TBL] [Abstract][Full Text] [Related]
19. Protein design of an HIV-1 entry inhibitor.
Root MJ; Kay MS; Kim PS
Science; 2001 Feb; 291(5505):884-8. PubMed ID: 11229405
[TBL] [Abstract][Full Text] [Related]
20. Structural and biological mimicry of protein surface recognition by alpha/beta-peptide foldamers.
Horne WS; Johnson LM; Ketas TJ; Klasse PJ; Lu M; Moore JP; Gellman SH
Proc Natl Acad Sci U S A; 2009 Sep; 106(35):14751-6. PubMed ID: 19706443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
